Ассоциация полиморфизма +405C > G (rs2010963) с подверженностью к метаболическому синдрому: кардио-метаболические факторы риска и концентрация матриксной металлопротеиназы-3
- Авторы: Никниаз Л.1,2, Аббасализад-Фарханги М.2
-
Учреждения:
- Исследовательский центр Управления Медицинскими услугами
- Тебризский университет медицинских наук
- Выпуск: Том 19, № 3 (2021)
- Страницы: 263-271
- Раздел: Экологическая генетика человека
- Статья получена: 07.05.2021
- Статья одобрена: 25.08.2021
- Статья опубликована: 10.10.2021
- URL: https://journals.eco-vector.com/ecolgenet/article/view/70303
- DOI: https://doi.org/10.17816/ecogen70303
- ID: 70303
Цитировать
Аннотация
В настоящем исследовании мы изучали роль нуклеотидной замены +405 в гене VEGF в патогенезе метаболического синдрома и анализировали ее связь с несколькими биохимичесимим факторами риска. Было генотипировано 150 пациентов с метаболическим синдромом и 50 здоровых людей с помощью PCR-RFLP. Биохимические показатели в сыворотке оценивали с помощью ELISA. Среди пациентов с метаболическим синдромом преобладал генотип CG. У них же было повышено содержание триглицеридов, снижено содержание липопротеинов высокой плотности и аланинаминотрансферазы. Показано, что изучаемая замена может быть предиктором метаболических нарушений при метаболическом синдроме. Подтверждение этого вывода требует увеличения выборки.
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Лейла Никниаз
Исследовательский центр Управления Медицинскими услугами; Тебризский университет медицинских наук
Email: nikniaz@yahoo.com
Scopus Author ID: 25031589500
Иран, Тебриз, ул. Аттар Нейшабури
Махди Аббасализад-Фарханги
Тебризский университет медицинских наук
Автор, ответственный за переписку.
Email: abbasalizad_m@yahoo.com
Иран, Тебриз, ул. Аттар Нейшабури
Список литературы
- Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. doi: 10.2337/diab.37.12.1595
- Heshmat R, Hemati Z, Qorbani M, et al. Metabolic syndrome and associated factors in Iranian children and adolescents: the CASPIAN-V study. J Cardiovasc Thorac Res. 2018;10(4):214–220. doi: 10.15171/jcvtr.2018.37
- Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Transl Res. 2017;183:14–25. doi: 10.1016/j.trsl.2016.12.004
- Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clinics in liver disease. 2018;22(1):133–140. doi: 10.1016/j.cld.2017.08.010
- Ghanei Gheshlagh R, Parizad N, Sayehmiri K. The relationship between depression and metabolic syndrome: systematic review and meta-analysis study. Iran Red Crescent Med J. 2016;18: e26523-e. doi: 10.5812/ircmj.26523
- Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi: 10.1016/j.jacc.2010.05.034
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359. doi: 10.1001/jama.287.3.356
- Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATP III and the WHO definitions. Diabetes Res Clin Pract. 2007;77(2) 251–257. doi: 10.1016/j.diabres.2006.12.001
- Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483–1488. doi: 10.1007/s00125-003-1221-6
- Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–1235. doi: 10.1006/cyto.2000.0692
- Kim YR, Hohong S. Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome. Biomed Rep. 2015;3(3):319–326. doi: 10.3892/br.2015.423
- Moradzadegan A, Vaisi-Raygani A, Nikzamir A, Rahimi Z. Angiotensin converting enzyme insertion/deletion (I/D)(rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. J Renin Angiotensin Aldosterone Syst. 2015;16:672–680. doi: 10.1177/1470320313497819
- Ray D, Mishra M, Ralph S, et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004;53(3):861–864. doi: 10.2337/diabetes.53.3.861
- Zafar MI, Mills K, Ye X, et al. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetology & metabolic syndrome. 2018;10:62–72. doi: 10.1186/s13098-018-0363-0
- Siervo M, Ruggiero D, Sorice R, et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition. 2012;28(3):262–266. doi: 10.1016/j.nut.2011.06.007
- Kimura K, Hashiguchi T, Deguchi T, et al. Serum VEGF – as a prognostic factor of atherosclerosis. Atherosclerosis. 2007;194(1):182–188. doi: 10.1016/j.atherosclerosis.2006.07.025
- Szaflik JP, Wysocki T, Kowalski M, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:39–43. doi: 10.1007/s00417-007-0674-6
- Petrovič D, Verhovec R, Petrovič MG, et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology. 2007;107(4):291–295. doi: 10.1159/000099064
- Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012;490:426–430. doi: 10.1038/nature11464
- Kanaki T, Bujo H, Mori S, et al. Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3. Biochem Biophys Res Commun. 2002;294(2):231–237. doi: 10.1016/S0006-291X(02)00468-0
- Silvestre JS, Mallat Z, Tamarat R, et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001;89(3):259–264. doi: 10.1161/hh1501.094269
- Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11(1): S37–S43. doi: 10.1016/S0962-8924(01)82222-4
- Murphy G, Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 2011;278(1):2–15. doi: 10.1111/j.1742-4658.2010.07918.x
- Thorp E. Contrasting inflammation resolution during atherosclerosis and post myocardial infarction at the level of monocyte/macrophage phagocytic clearance. Front Immunol. 2012;3:39–49. doi: 10.3389/fimmu.2012.00039
- Lijnen HR, Maquoi E, Demeulemeester D, et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost. 2002;88(2):345–353. doi: 10.1055/s-0037-1613208
- Gummesson A, Hägg D, Olson FJ, et al. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest. 2009;69:636–642. doi: 10.3109/00365510902912747
- Miksztowicz V, Muzzio ML, Royer M, et al. Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism. 2008;57(11):1493–1496. doi: 10.1016/j.metabol.2008.06.001
- Cicero AFG, Derosa G, Manca M, et al. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium. 2007;14(4–5):193–198. doi: 10.1080/10623320701606731
- Barylski M, Kowalczyk E, Banach M, et al. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology. 2009;60(1): 87–92. doi: 10.1177/0003319708327165
- Farzi A, Hagh MF. Association between Vascular Endothelial Growth Factor (VEGF) +405 C/G polymorphism and hypertension in North West of Iran. Int Res J App Bas Sci. 2014;8:122–125.
- Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;22(3):827–832. doi: 10.1093/ndt/gfl641
- Jahangiry L, Shojaeizadeh D, Najafi M, et al. ‘Red Ruby’: an interactive web-based intervention for lifestyle modification on metabolic syndrome: a study protocol for a randomized controlled trial. BMC Public Health. 2014;14:748–754. doi: 10.1186/1471-2458-14-748
- Jahangiry L, Shojaeizadeh D, Najafi M, et al. ‘Red Ruby’: an interactive web-based intervention for lifestyle modification on metabolic syndrome: a study protocol for a randomized controlled trial. BMC public health. 2014;14(1):748. doi: 10.1186/1471-2458-14-748
- Farhangi MA, Jahangiry L, Mirinazhad MM, et al. A web-based interactive lifestyle modification program improves lipid profile and serum adiponectin concentrations in patients with metabolic syndrome: the “Red Ruby” study. Int J Diab Dev C. 2015;37:21–30. doi: 10.1007/s13410-015-0395-z
- Mirinazhad MM, Farhangi MA, Jahangiri L, Yaghoubi A. Serum adiponectin concentrations in relation to lipid proffle, anthropometric variables and insulin resistance in patients with metabolic syndrome. Malay J Nutr. 2014;20:283–289.
- Douvaras P, Antonatos DG, Kekou K, et al. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology. 2009;114(1):11–18. doi: 10.1159/000210189
- Miller SA, Dykes DD, Polesky HFRN. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215–1219. doi: 10.1093/nar/16.3.1215
- Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635–1639. doi: 10.2337/diabetes.51.5.1635
- Kowalski J, Sliwczyńska-Rodziewicz D, Kowalczyk E, et al. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol Merkur Lekarski. 2011;30:249–252.
- Altinkaya SO, Ugur M, Ceylaner G, et al. Vascular endothelial growth factor +405 C/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women. Arch Gynecol Obstet. 2011;283:267–272. doi: 10.1007/s00404-009-1344-1
- Kim OkJ, Hong SH, Oh SH, et al. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. Stroke. 2011;42(9):2393–2402. doi: 10.1161/STROKEAHA.110.607739
- Huez I, Bornes S, Bresson D, et al. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol. 2001;15(12):2197–2210. doi: 10.1210/mend.15.12.0738
- Vander Meer P, de Boer RA, White HL, et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail. 2005;11(4):279–284. doi: 10.1016/j.cardfail.2004.11.006
Дополнительные файлы
![](/img/style/loading.gif)